Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

[1]  I. Pavord,et al.  Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. , 2020, The Lancet. Respiratory medicine.

[2]  L. Heaney,et al.  Different endotypes and phenotypes drive the heterogeneity in severe asthma , 2020, Allergy.

[3]  D. Price,et al.  Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management , 2020, American journal of respiratory and critical care medicine.

[4]  R. Chaudhuri,et al.  Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study , 2019, Thorax.

[5]  M. Humbert,et al.  Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus , 2018, ERJ Open Research.

[6]  G. Canonica,et al.  Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. , 2018, Journal of Allergy and Clinical Immunology: In Practice.

[7]  I. Pavord,et al.  A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial , 2018, Trials.

[8]  Richard Beasley,et al.  After asthma: redefining airways diseases , 2017, The Lancet.

[9]  C. Jenkins,et al.  Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[10]  D. Price,et al.  Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry , 2016, Thorax.

[11]  I. Pavord,et al.  Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK) , 2015, Thorax.

[12]  E. R. Sutherland,et al.  A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. , 2012, American journal of respiratory and critical care medicine.

[13]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[14]  A. Chang,et al.  A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils) , 2010, Thorax.

[15]  Barmak Modrek,et al.  T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.

[16]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[17]  L. Boulet,et al.  Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations , 2006, European Respiratory Journal.

[18]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[19]  I. Pavord,et al.  Non-eosinophilic cor ticosteroid unresponsive asthma , 1999, The Lancet.